Index sorted by Drug, Company, and Foundations and Nonprofit/Government Organizations
Recent advancements in cancer treatments have revolutionized cancer care. The use of genetic mutations to guide therapy, and continued innovations in immunotherapies, targeted drugs, radiation, and chemotherapy have improved patients’ health outcomes and quality of life.
It is no secret that the cost of cancer drugs continues to escalate, resulting in significant financial burden for patients. And when it comes to cancer, the financial stress is compounded by the enormous emotional stress associated with a cancer diagnosis, which can affect survival.
AbbVie, together with Genentech, has developed and is marketing the oncology drug Venclexta (venetoclax). Venclexta is indicated for patients with chronic lymphocytic leukemia and 17p deletion who have received at least 1 treatment, and for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma with or without 17p deletion after 1 treatment.
Agios Pharmaceuticals offers the myAgios Patient Support Services, a program that provides a suite of support services for patients who have been prescribed Tibsovo (ivosidenib).
Amgen Assist 360 provides several support services for insured, uninsured, and underinsured patients who encounter financial hardships and cannot afford the Amgen medications they are prescribed, including Amgen FIRST STEP and the Amgen Safety Net Foundation.
Array BioPharma, via its ArrayACTS patient support program, offers several financial assistance options and support services for patients who have been prescribed the combination of Braftovi (encorafenib) and Mektovi (binimetinib) but who cannot afford to pay for them.
Astellas Pharma’s Xtandi Support Solutions offers patient assistance services to eligible patients who are prescribed Xtandi (enzalutamide) for the treatment of castration-resistant prostate cancer (CRPC) or for metastatic CRPC.
AstraZeneca, through its Access 360 and AZ&Me programs, offers a range of patient support programs and drug-specific patient savings programs to help patients access affordable AstraZeneca medications.